Analysis of pegylated interferon alpha-2a efficacy in the treatment of chronic hepatitis C / 中国基层医药

ABSTRACT

Objective To investigate the clinical efficacy and safety of the pegylated interferon alpha-2a (PEG-IFN-a-2a)in treatment of chronic hepatitis C.Methods 170 cases of patients with chronic hepatitis C were included in the study,by using digital table method they were randomly divided into two groups,the observation group of 85 cases were treated with PEG-IFN-alpha-2a therapy,and 85 cases in the control group using ordinary interferon alpha-2b therapy.Curative effect and safety of two groups of patients were compared.Results The obser-vation group treated for 12 weeks,24 weeks and 24 weeks of alanine aminotransferase (ALT)and improvement rate were respectively 70.59%,80%,92.94%,which were higher than that of the control group (52.94%,62.35% and 70.58%)(χ2 =5.42,6.71,4.83,all P<0.05).The observation group for 12 weeks,24 weeks and 24 weeks of HCV-RNA negative rate were 64.71%,75.29%and 91.76%,obviously were higher than the control group of50.59%, 61.18% and 70.59% (χ2 =4.28,7.68,6.31,all P<0.05).Adverse reaction rates were not statistically signifi-cant.Conclusion The pegylated interferon alpha-2a (PEG-IFN-a-2a)in treatment of chronic hepatitis C has a significant curative effect of PEG-IFN-alpha-2a therapy in chronic hepatitis C,which is better than the ordinary interferon alpha-2b,and is worthy of extensive promotion and application.